ROLE OF COMPLEMENT ACTIVATION IN HYPERSENSITIVITY REACTIONS TO DOXIL AND HYNIC PEG LIPOSOMES: EXPERIMENTAL AND CLINICAL STUDIES
- 1 January 2002
- journal article
- Published by Taylor & Francis in Journal of Liposome Research
- Vol. 12 (1-2), 165-172
- https://doi.org/10.1081/lpr-120004790
Abstract
Pegylated liposomal doxorubicin (Doxil) and 99mTc-HYNIC PEG liposomes (HPL) were reported earlier to cause hypersensitivity reactions (HSRs) in a substantial percentage of patients treated i.v. with these formulations. Here we report that (1) Doxil, HPL, pegylated phosphatidylethanolamine (PEG-PE)-containing empty liposomes matched with Doxil and HPL in size and lipid composition, and phosphatidylglycerol (PG)-containing negatively charged vesicles were potent C activators in human serum in vitro, whereas small neutral liposomes caused no C activation. (2) Doxil and other size-matched PEG-PE and/or PG-containing liposomes also caused massive cardiopulmonary distress with anaphylactoid shock in pigs via C activation, whereas equivalent neutral liposomes caused no hemodynamic changes. (3) A clinical study showed more frequent and greater C activation in patients displaying HSR than in non-reactive patients. These data suggest that liposome-induced HSRs in susceptible individuals may be due to C activation, which, in turn, is due to the presence of negatively charged PEG-PE in these vesicles.Keywords
This publication has 10 references indexed in Scilit:
- Liposomal encapsulated anthracyclines: new therapeutic horizonsCurrent Oncology Reports, 2001
- Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of ChemotherapyCancer Investigation, 2001
- Sch-28080 depletes intracellular ATP selectively in mIMCD-3 cellsAmerican Journal of Physiology-Cell Physiology, 2000
- Tc-99m-PEG-Liposomes for the Evaluation of Colitis in Crohn's DiseaseJournal of Drug Targeting, 2000
- The Role of Complement Activation in Hypersensitivity to Pegylated Liposomal Doxorubicin (Doxil®)Journal of Liposome Research, 2000
- Liposomal Doxorubicin and Conventionally Fractionated Radiotherapy in the Treatment of Locally Advanced Non–Small-Cell Lung Cancer and Head and Neck CancerJournal of Clinical Oncology, 1999
- Hemodynamic Changes Induced by Liposomes and Liposome-Encapsulated Hemoglobin in PigsCirculation, 1999
- Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.Journal of Clinical Oncology, 1995
- Clinical Studies of Liposome-Encapsulated DoxorubicinActa Oncologica, 1994
- The membrane attack complexSpringer Seminars in Immunopathology, 1984